Sum Up The Pieces: IAK Could Be Worth $147
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares U.S. Insurance ETF (IAK) has an implied analyst target price of $147.31, indicating a potential 10.77% upside from its current trading price of $132.99. Notable underlying holdings with significant upside include Oscar Health Inc, CNO Financial Group Inc, and HCI Group Inc.
Investor Research Considerations: Analysts' target prices may reflect optimism or could be outdated based on recent developments, prompting the need for further investor research to assess the validity of these targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OSCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OSCR
Wall Street analysts forecast OSCR stock price to fall
8 Analyst Rating
1 Buy
4 Hold
3 Sell
Hold
Current: 28.910
Low
11.00
Averages
15.75
High
25.00
Current: 28.910
Low
11.00
Averages
15.75
High
25.00
About OSCR
Oscar Health, Inc. is a healthcare technology company built around a full stack technology platform. The Company's offerings include its insurance business and +Oscar Platform. Its health plans are offered in the individual market. The individual market primarily consists of policies purchased by individuals and families through health insurance marketplaces, established by the ACA and operated by the federal government, as well as other marketplaces operated by individual states. Individuals and families may also purchase policies in the individual market off-exchange. Employees whose employers have chosen to offer an Individual Coverage Health Reimbursement Arrangement (ICHRA) are also able to purchase its health plans. It offers health plans in the individual market under the five metal plan categories defined by the ACA: Catastrophic, Bronze, Silver, Gold, and Platinum. Through the +Oscar platform, the Company deploys its technology to help others throughout the healthcare system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Applied Materials Opens $500M Singapore Campus, Hits 52-Week High
- Manufacturing Expansion: Applied Materials opened its $500 million Tampines Campus in Singapore, leading its stock to reach a 52-week high of $534.44 on Wednesday, with the new facility more than doubling cleanroom space and helping semiconductor manufacturers meet the growing demand from AI-related technologies, thereby enhancing the company's future growth potential.
- Telecom Technology Milestone: AmpliTech shares climbed to a five-year high of $8.29 after successfully participating in the O-RAN ALLIANCE Global PlugFest, where its advanced radio technology demonstrated interoperability with major telecommunications operators' equipment, marking a significant step toward broader commercial adoption of its 5G infrastructure products and strengthening its position within the Open RAN ecosystem.
- Analyst Rating Upgrade: Oscar Health received support from Barclays analyst Andrew Mok, who upgraded the stock from 'Equal Weight' to 'Overweight' and raised the price target from $30 to $35, noting that Oscar provides investors with a direct way to benefit from growth in the Affordable Care Act insurance market, with greater gains expected if demand for ACA plans continues to rise.
- Strong Market Performance: Despite a broader market pause, shares of Applied Materials, AmpliTech, and Oscar Health all reached new 52-week highs on Wednesday, with AMAT and OSCR stocks surging 93% year-to-date, while AMPG stock jumped over 154%, reflecting strong investor confidence in the future growth of these companies.
See More
Amazon's Logistics Expansion Hits Freight Stocks Hard
- Freight Stocks Decline: Amazon's announcement to open its less-than-truckload shipping services to external companies led to a 5% drop in FedEx Freight and Old Dominion Freight Line, and a 4% decline in XPO, indicating a significant threat to industry incumbents and potential market share erosion.
- Super Micro Stock Plunge: Super Micro Computer's plan to raise $7 billion through equity and equity-linked securities to cover hardware component costs resulted in an 18% stock drop, reflecting market concerns over its financing strategy and potential long-term implications for growth.
- Energy Stocks Rally: Devon Energy's stock surged over 6% after Evercore ISI upgraded its rating to outperform, following a better-than-expected mid-month update post the $58 billion acquisition of Coterra Energy, showcasing strong performance in the oil and gas sector.
- Restaurant Stocks Surge: Cracker Barrel's stock soared 24% after raising its full-year revenue and adjusted EBITDA guidance, reporting fiscal Q3 earnings of $0.29 per share on $797.4 million in revenue, exceeding analyst expectations and indicating robust business recovery.
See More
Latest Wall Street Ratings Overview
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Apple Launches Revamped Siri AI Assistant at WWDC
- Siri AI Upgrade: At WWDC, Apple unveiled a revamped Siri AI assistant powered in part by Google Gemini technology, designed to handle complex tasks across devices, enhancing user information retrieval efficiency, although the stock fell over 1% after reaching an all-time high.
- Oscar Health Growth Outlook: Oscar Health reaffirmed its 2026 revenue forecast of $18.7 billion to $19 billion, with the CFO noting a strong start to the fiscal year supported by stable membership trends and favorable industry data, leading to a five-year high stock price of $27.59 and a shift to 'extremely bullish' retail sentiment.
- Eli Lilly Market Leadership: Eli Lilly's stock hit a record high of $1,182.73 following positive late-stage trial results for Foundayo, its oral obesity drug, showcasing competitive advantages in Type 2 diabetes treatment, with plans to seek regulatory approval for this indication.
- Stock Performance Review: Year-to-date, AAPL and LLY stocks have gained nearly 9% and 7%, respectively, while OSCR stock surged 90%, reflecting investor enthusiasm driven by developments in artificial intelligence and encouraging healthcare data, propelling all three companies to fresh 52-week highs.
See More
Oscar Health's 2026 Outlook Remains Optimistic
- Strong Start to 2026: CFO Scott Blackley stated that 2026 is off to a strong start with membership tracking as expected and May healthcare utilization performing better than anticipated, indicating resilience and potential growth opportunities for the company in the market.
- Financial Performance Exceeds Expectations: Oscar Health reported a first-quarter EPS of $2.07, surpassing the $1.10 estimate, while revenue reached $4.65 billion, although below the $4.92 billion forecast, with adjusted EBITDA hitting $727 million, showcasing enhanced profitability.
- Market Opportunities Amid Challenges: Despite expectations of a 20% to 30% contraction in the ACA market, Blackley highlighted competitor withdrawals as growth opportunities, particularly in overlapping markets, which could lead to increased market share by 2027.
- Investor Sentiment Extremely Bullish: According to Stocktwits, retail sentiment for OSCR is extremely bullish, with a 1,283% surge in message volume over 24 hours, reflecting strong market confidence in Oscar's future performance.
See More
Applied Materials Opens $500M Singapore Campus, Hits 52-Week High
- Manufacturing Expansion: Applied Materials opened its $500 million Tampines Campus in Singapore, leading its stock to reach a 52-week high of $534.44 on Wednesday, with the new facility more than doubling cleanroom space and helping semiconductor manufacturers meet the growing demand from AI-related technologies, thereby enhancing the company's future growth potential.
- Telecom Technology Milestone: AmpliTech shares climbed to a five-year high of $8.29 after successfully participating in the O-RAN ALLIANCE Global PlugFest, where its advanced radio technology demonstrated interoperability with major telecommunications operators' equipment, marking a significant step toward broader commercial adoption of its 5G infrastructure products and strengthening its position within the Open RAN ecosystem.
- Analyst Rating Upgrade: Oscar Health received support from Barclays analyst Andrew Mok, who upgraded the stock from 'Equal Weight' to 'Overweight' and raised the price target from $30 to $35, noting that Oscar provides investors with a direct way to benefit from growth in the Affordable Care Act insurance market, with greater gains expected if demand for ACA plans continues to rise.
- Strong Market Performance: Despite a broader market pause, shares of Applied Materials, AmpliTech, and Oscar Health all reached new 52-week highs on Wednesday, with AMAT and OSCR stocks surging 93% year-to-date, while AMPG stock jumped over 154%, reflecting strong investor confidence in the future growth of these companies.
See More
Amazon's Logistics Expansion Hits Freight Stocks Hard
- Freight Stocks Decline: Amazon's announcement to open its less-than-truckload shipping services to external companies led to a 5% drop in FedEx Freight and Old Dominion Freight Line, and a 4% decline in XPO, indicating a significant threat to industry incumbents and potential market share erosion.
- Super Micro Stock Plunge: Super Micro Computer's plan to raise $7 billion through equity and equity-linked securities to cover hardware component costs resulted in an 18% stock drop, reflecting market concerns over its financing strategy and potential long-term implications for growth.
- Energy Stocks Rally: Devon Energy's stock surged over 6% after Evercore ISI upgraded its rating to outperform, following a better-than-expected mid-month update post the $58 billion acquisition of Coterra Energy, showcasing strong performance in the oil and gas sector.
- Restaurant Stocks Surge: Cracker Barrel's stock soared 24% after raising its full-year revenue and adjusted EBITDA guidance, reporting fiscal Q3 earnings of $0.29 per share on $797.4 million in revenue, exceeding analyst expectations and indicating robust business recovery.
See More
Latest Wall Street Ratings Overview
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Apple Launches Revamped Siri AI Assistant at WWDC
- Siri AI Upgrade: At WWDC, Apple unveiled a revamped Siri AI assistant powered in part by Google Gemini technology, designed to handle complex tasks across devices, enhancing user information retrieval efficiency, although the stock fell over 1% after reaching an all-time high.
- Oscar Health Growth Outlook: Oscar Health reaffirmed its 2026 revenue forecast of $18.7 billion to $19 billion, with the CFO noting a strong start to the fiscal year supported by stable membership trends and favorable industry data, leading to a five-year high stock price of $27.59 and a shift to 'extremely bullish' retail sentiment.
- Eli Lilly Market Leadership: Eli Lilly's stock hit a record high of $1,182.73 following positive late-stage trial results for Foundayo, its oral obesity drug, showcasing competitive advantages in Type 2 diabetes treatment, with plans to seek regulatory approval for this indication.
- Stock Performance Review: Year-to-date, AAPL and LLY stocks have gained nearly 9% and 7%, respectively, while OSCR stock surged 90%, reflecting investor enthusiasm driven by developments in artificial intelligence and encouraging healthcare data, propelling all three companies to fresh 52-week highs.
See More
Oscar Health's 2026 Outlook Remains Optimistic
- Strong Start to 2026: CFO Scott Blackley stated that 2026 is off to a strong start with membership tracking as expected and May healthcare utilization performing better than anticipated, indicating resilience and potential growth opportunities for the company in the market.
- Financial Performance Exceeds Expectations: Oscar Health reported a first-quarter EPS of $2.07, surpassing the $1.10 estimate, while revenue reached $4.65 billion, although below the $4.92 billion forecast, with adjusted EBITDA hitting $727 million, showcasing enhanced profitability.
- Market Opportunities Amid Challenges: Despite expectations of a 20% to 30% contraction in the ACA market, Blackley highlighted competitor withdrawals as growth opportunities, particularly in overlapping markets, which could lead to increased market share by 2027.
- Investor Sentiment Extremely Bullish: According to Stocktwits, retail sentiment for OSCR is extremely bullish, with a 1,283% surge in message volume over 24 hours, reflecting strong market confidence in Oscar's future performance.
See More
